Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Daiichi Sankyo receives manufacturing and marketing approval for Efient tablet


Monday, 24 Mar 2014 02:00am EDT 

Daiichi Sankyo Co Ltd:Received approval from the Ministry of Health, Labor and Welfare in Japan for the antiplatelet agent Efient 3.75mg/5mg tablets (JAN: Prasugrel Hydrochloride), for the treatment of patients with ischemic heart disease undergoing percutaneous coronary intervention (PCI).Efient is an oral antiplatelet agent which reduces incidence of ischemic events in perioperative period of PCI by reducing platelet aggregation activity.